Office of Public Relations
First U.S. patient treated with lung volume reduction coils in severe emphysema study
MUSC Bronchoscopy team places implant to improve lung function and quality of life
For Immediate Release
Contact: Rebekah Wright
March 4, 2013
CHARLESTON – The Medical University of South Carolina’s (MUSC) Charlie Strange, M.D., treated the first patient in the United States in the RENEW Study. The study is evaluating the use of PneumRx, Inc.'s RePneu® Lung Volume Reduction Coil (LVRC) in patients with severe emphysema. The RePneu® LVRC, a minimally invasive medical implant designed to treat the symptoms of severe emphysema, is intended to improve lung function, exercise ability and quality of life for this underserved patient population.
“After learning the LVRC procedure in Europe, I am thrilled to offer this innovative treatment through our team at MUSC," said Strange, MUSC professor of pulmonary and critical care, allergy and sleep medicine and principal investigator for the RENEW study. The coils are offered through a prospective, randomized research trial for patients with lung hyperinflation from emphysema. Ten coils are placed in a lung lobe with severe emphysema to reduce the size of the hyper-inflated lung and to give it more elastic recoil. The other lung is treated after four months. The LVRC procedure remains investigational at this time and can only be accessed in South Carolina through this trial.
Although the LVRC is undergoing clinical evaluation in the United States, it has been used in Europe since 2008. The technology is CE Mark approved in Europe and routinely available to treat patients in Germany. It was the only emphysema treatment method selected in 2012 by the French Ministry of Health to undergo a multi-center cost-effectiveness study in France. Unlike other minimally invasive devices designed to treat emphysema, the RePneu LVRC is intended to treat a broad range of emphysema patients, including those with heterogeneous and homogeneous disease, in both upper and lower lobes, and it performs independently of collateral ventilation, a common condition in emphysema patients.
MUSC’s South Carolina Clinical & Translational Research (SCTR) Navigation Service negotiated facility access and expedited the research timeline to make the study possible. The multidisciplinary collaboration included the MUSC bronchoscopy team, Strange’s research staff, and the MUSC Hospital Authority 10 East staff. For more information about MUSC’s SCTR Institute, please contact email@example.com or (843) 792-8300 or visit the website.
Visit these websites for more information about the RePneu LVRC and the RENEW study.
The South Carolina Clinical & Translational Research Institute (SCTR) of the Medical University of South Carolina is the catalyst for changing the culture of biomedical research, facilitating sharing of resources and expertise, and streamlining research-related processes to bring about large-scale change in the clinical and translational research efforts in South Carolina. The SCTR Institute was established in 2006 in response to the National Institute of Health’s Clinical and Translational Science Award Program, funded by the NIH/National Center for Advancing Translational Sciences (NIH/NCATS Grant UL1 TR000062). For more information, visit sctr.musc.edu.
Founded in 1824 in Charleston, the Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $1.7 billion. MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), and a leading Institute of Psychiatry. For more information on academic information or clinical services, visit musc.edu.
About the MUSC Pulmonary and Critical Care, Allergy and Sleep Division
The Pulmonary Division includes 20 physicians who perform clinical care, education and research in a variety of lung diseases. These members of the MUSC Department of Medicine have specialized programs in COPD and Alpha-1 Antitrypsin Deficiency, Lung Cancer, Sarcoidosis and Interstitial Lung Disease, Pulmonary Hypertension, Sleep, Allergy, Cystic Fibrosis, and Critical Care Medicine. Interventional Bronchoscopy services were used to facilitate the RENEW Study enrollment. For more information see http://clinicaldepartments.musc.edu/medicine/divisions/pulmonary/index.htm